Generic Name and Formulations:
Clonidine 0.1mg/day, 0.2mg/day, 0.3mg/day; each transdermal patch delivers dose for 1 week.
Boehringer Ingelheim Pharmaceuticals
Indications for CATAPRES-TTS:
Apply to intact, hairless area of upper arm or anterior torso; rotate application sites. Taper withdrawal of other antihypertensives. Initially one 0.1mg/day patch weekly; may increase after 1–2 weeks; max 0.6mg/day.
Sinus node dysfunction. AV block. Pheochromocytoma: not effective. Conduction disturbances. Renal dysfunction. Avoid abrupt cessation. If local reaction occurs from patch, using tabs may cause generalized rash. Discontinue 4hrs before surgery; resume as soon as possible after surgery. Patch: remove before defibrillation, cardioversion, or MRI. Pregnancy (Cat.C). Nursing mothers.
Antagonized by tricyclic antidepressants. Potentiates CNS depressants. Orthostatic regulation disturbances (eg, orthostatic hypotension, dizziness, fatigue) possible with neuroleptics. Monitor heart rate in patients receiving agents known to affect sinus node function or AV nodal conduction (eg, digitalis, calcium channel blockers, β-blockers).
Central alpha agonist.
Dry mouth, dry eye, drowsiness, dizziness, weakness, constipation, sedation, rash, myalgia, urticaria, nausea, insomnia, agitation, orthostatic hypotension, impotence, arrhythmias.